Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Liver cancer battle: which combo therapy wins?

NCT ID NCT07340502

Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two treatment combinations for advanced liver cancer that cannot be removed by surgery. One group gets TACE (a procedure that blocks blood flow to the tumor and delivers chemo directly) plus immunotherapy and a targeted drug. The other group gets HAIC (a continuous chemo infusion through a catheter) plus the same drugs. The goal is to see which approach works better and is safer. About 364 adults with newly diagnosed liver cancer will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PD-1 inhibitors and lenvatinib
What this could lead to
If this study shows HAIC is better than TACE for certain patients, it could lead to more effective, personalized treatment for advanced liver cancer.
What could go wrong
This is an observational study, not a randomized trial, so results may be less definitive. It is also early-stage, and the treatments have known side effects like fatigue, liver damage, and bleeding risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 364 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This is a multicenter, prospective, observational cohort study designed to evaluate the efficacy and safety, primarily in terms of progression-free survival (PFS), of transarterial chemoembolization (TACE) versus hepatic arterial infusion chemotherapy (HAIC), each combined with a PD-1 inhibitor and lenvatinib, in the treatment of unresectable hepatocellular carcinoma (HCC). The study plans to enroll a total of 364 patients, who will be prospectively followed for treatment efficacy and adverse events. The primary endpoint is PFS. Secondary endpoints include the objective response rate (ORR), overall survival (OS), and safety.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged between 18 and 75 years; * Tumor stage classified as BCLC-A to -C, with no evidence of extrahepatic metastasis; * Newly diagnosed, treatment-naïve hepatocellular carcinoma with no prior anticancer therapy; * Child-Pugh liver function score ≤ 7; * Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1; * Absence of severe organic diseases affecting major organs (e.g., heart, lung, brain). Exclusion Criteria: * Decompensated liver cirrhosis; * Concurrent other malignancies or recurrent hepatocellular carcinoma; * Any active, known, or suspected autoimmune disease; * History of hypersensitivity to any component of PD-1 inhibitors or lenvatinib; * Human immunodeficiency virus (HIV) infection; or active viral hepatitis (e.g., hepatitis B or C); * Tumor thrombus involving the inferior vena cava, hepatic veins, or the main portal vein trunk.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.